Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neuromed Pharmaceuticals Ltd.

Division of Epirus Biopharmaceuticals Inc.
www.neuromed.com

Latest From Synaptica Ltd.

Scottish life science cluster rides the translational medicine wave

Translational medicine, stem cell therapy, personalised medicine and open collaboration: all are key factors in steering drug research towards a more productive future. And all are being brought together on a burgeoning science campus near Edinburgh that aims to draw the attention of the biopharmaceutical industry and investors and facilitate the launch of a dozen innovative spin-out companies over the next few years.

Metabolic Disorders Cancer

Edinburgh BioQuarter to spin out first companies

The new Edinburgh BioQuarter initiative in Scotland will be launching its first two bioscience spin-out companies in the coming weeks, its commercial director Dr Michael Capaldi told Scrip. These are likely to be followed by a further two or three companies by the end of the year. The companies will span a range of bioscience areas, from therapeutics - including orphan drugs, to devices and diagnostics.

Faust Pharmaceuticals

Strasbourg, France-based Faust Pharmaceuticals aims to identify and develop small molecule drug candidates that can modulate the level of neurotransmitters in the brain to treat neurodegenerative disorders including Parkinson's Disease and Alzheimer's Disease.
BioPharmaceutical Europe

Faust Pharmaceuticals

Strasbourg, France-based Faust Pharmaceuticals aims to identify and develop small molecule drug candidates that can modulate the level of neurotransmitters in the brain to treat neurodegenerative disorders including Parkinson's Disease and Alzheimer's Disease.
BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Neuromed Technologies Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Epirus Biopharmaceuticals Inc.
  • Senior Management
  • Bruce S Colwill, CFO
    Jeffrey Acara, VP, Bus. Dev.
    Terrance P Snutch, PhD, CSO
    Mario Orlando, VP, Mktg.
  • Contact Info
  • Neuromed Pharmaceuticals Ltd.
    Phone: (604) 909-2530
    301-2389 Health Sciences Mall, UBC
    Don Rix Bldg.
    Vancouver, V6T 1Z3
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register